These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1102243)

  • 1. Panel 4: phase IV investigations.
    Blackwell B; Stolley PD; Buncher R; Klimt CR; Temple R; Venn D; Wardell WM
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 2):653-6. PubMed ID: 1102243
    [No Abstract]   [Full Text] [Related]  

  • 2. Panel 3: phase III investigations.
    Azarnoff DL; Abrams WB; Cuttner J; Hewitt WL; Hailman HF
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 2):650-2. PubMed ID: 1102242
    [No Abstract]   [Full Text] [Related]  

  • 3. Report of the Seventh European Symposium on Clinical Pharmacological Evaluation in Drug control. Deidesheim, 14--17 November 1978.
    Eur J Clin Pharmacol; 1979 Apr; 15(3):199-209. PubMed ID: 37092
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical biostatistics. 28. The biostatistical problems of pharmaceutical surveillance.
    Feinstein AR
    Clin Pharmacol Ther; 1974 Jul; 16(1):110-23. PubMed ID: 4843239
    [No Abstract]   [Full Text] [Related]  

  • 5. Epidemiological observation on drug-induced illness.
    Jick H
    Curr Top Pathol; 1980; 69():1-15. PubMed ID: 7016466
    [No Abstract]   [Full Text] [Related]  

  • 6. Assuring the safety and efficacy of therapies.
    Stolley PD
    Int J Health Serv; 1974; 4(1):131-45. PubMed ID: 4597990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reactions: the need for detection and control.
    Cluff LE
    Am J Epidemiol; 1971 Nov; 94(5):405-8. PubMed ID: 5120538
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems.
    Venning GR
    Br Med J (Clin Res Ed); 1983 Feb; 286(6363):458-60. PubMed ID: 6401562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [How to improve drug development and utilization in pediatrics].
    Pons G; Lassale C; Eschwege E
    Therapie; 1999; 54(4):423-32. PubMed ID: 10667109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panel 1: phase I investigations.
    Goldberg LI; Besselaar GH; Arnold JD; Lemberger L; Mitchell JR; Whitsett TL
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 2):643-6. PubMed ID: 1102240
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trials of new drugs.
    Dollery CT
    J R Coll Physicians Lond; 1977 Apr; 11(3):226-33. PubMed ID: 323473
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug trials: non-medical, non-pharmacological, non-psychiatric and non-psychological considerations.
    Amatu HI
    Niger Med J; 1979; 9(7-8):759-65. PubMed ID: 543314
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical trials of drugs from the viewpoint of the Food and Drug Administration.
    Crout JR
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 2):634-6. PubMed ID: 1102238
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trials in post-marketing surveillance of drugs.
    Bell RL; Smith EO
    Control Clin Trials; 1982 Mar; 3(1):61-8. PubMed ID: 7067472
    [No Abstract]   [Full Text] [Related]  

  • 15. Monitoring adverse reactions to drugs: toward a therapeutic audit.
    Wade OL; Beeley L
    Int J Health Serv; 1974; 4(1):109-23. PubMed ID: 4597989
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drugs: from research to consumer].
    Krankenpflege (Frankf); 1978 Nov; 32(11):366-8. PubMed ID: 213643
    [No Abstract]   [Full Text] [Related]  

  • 17. Statistical analyses of adverse event data from clinical trials. Special emphasis on serious events.
    O'Neill RT
    Drug Inf J; 1987; 21(1):9-20. PubMed ID: 10281640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case-control studies in the assessment of drug safety.
    Vessey MP
    Acta Med Scand Suppl; 1984; 683():29-33. PubMed ID: 6588736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How physicians choose their drugs.
    Lilja J
    Soc Sci Med (1967); 1976; 10(7-8):363-5. PubMed ID: 996572
    [No Abstract]   [Full Text] [Related]  

  • 20. Panel 2: phase II investigations.
    Hollister LE; Martz BL; Carr EA; Cohn HD; Crout JR; Levine J
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 2):647-9. PubMed ID: 1102241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.